ABSTRACT AIMS: Consumption of wine has a protective effect on cardiovascular diseases. Data from prospective, long-term, head-to-head comparisons of effects of different drinks on markers of atherosclerosis have been insuffi cient. METHODS AND RESULTS: In Vino Veritas (IVV) study is long-term, prospective, multi-centre, randomized trial comparing effects of red and white wine on atherosclerosis. 157 healthy subjects were randomized to white or red wine consumption for one year. We did not fi nd increase in HDL-cholesterol in the whole group (1.66±0.58 vs 1.62±0.49, p=0.180) or difference between both groups (1.60±0.53 vs 1.64±0.46, p=0.634). At 12 months there was reduction of LDL-cholesterol in both groups, but with no difference between the groups (3.37±0.75 vs 3.60±1.10, p=0.134); there was no difference between the groups in total cholesterol, CRP, fasting blood glucose and liver function tests. Both groups had comparable differences from baseline in levels of parameters of oxidative stress. CONCLUSION: We did not fi nd any clinically relevant differences in the lipid profi le, CRP, fasting blood glucose and other markers of atherosclerosis, between long-term consumption of red and white wine. Moreover, we were unable to confi rm the hypothesis that wine drinking is associated with an elevation of HDL (Tab. 7, Fig. 1, Ref. 30). Text in PDF www.elis.sk.
Introduction
The observation of the so-called "French paradox" by Renaud and Lorgeril in 1992 (1) started an enormous effort to discover the mechanisms behind the benefi cial effect of wine drinking on cardiovascular prognosis. Since the early '90s, a number of experimental and clinical studies have been published, describing the protective effect of red wine on different pathways of the pathogenesis of atherosclerosis. Antioxidants, fl avonoids and polyphenols became the fi rst substances contained in red wine with proven benefi cial effects in various diseases, such as inhibition of LDL oxidation or attenuation of ischemia-reperfusion injury (2) . However, several experimental studies have also shown that alcohol itself may have a protective impact (2) and these observations were confi rmed by data from large population-based studies and registries, showing cardiovascular benefi ts of drinking alcohol, regardless of type of beverage, with similar benefi ts shown for red and white wines, beer and even liquors (3, 4) . It has been shown in animal experiments and in vitro studies that there are major differences in basic characteristics between red and white wines. However, prospective data from long-term, head-to-head comparisons of the effects of red and white wines on markers of atherosclerosis are missing (5) .
Methods

Objective
The objective of the IVV trial is to compare the long-term effects of regular red and white wine drinking on the biomarkers of atherosclerosis.
Study overview
This is a prospective, multicentre, randomized, comparative study in healthy individuals with mild to moderate risk of cardiovascular disease. The study protocol, information for patient, and informed consent were reviewed and approved by a multicentre ethics committee as well as by local ethics committees in each institution before study initiation.
Eligible individuals were randomized to one of two arms: regular drinking of red wine (RW; Pinot Noir, 2008, Moravia, Czech Republic) or white wine (WW; Chardonnay-Pinot, 2008, Moravia, Czech Republic). Women with a body weight of less than 70 kg received 0.2 litres per day, women over 70 kg and men 0.3 litres per day. The chemical specifi cations of the respective wines are shown in Table 1 . Participants were followed on an intention-to-treat basis.
Study endpoints
The primary endpoint is the level of HDL-cholesterol.
The secondary endpoints are levels of other markers associated with the progression of atherosclerosis (total-and LDL-cholesterol, triglycerides, oxidized LDL, C-reactive protein, advanced oxidation protein product, myeloperoxidase, interleukin 6, interleukin 18, matrix metalloproteinases, glutathione s-transferase, monocyte chemoattractant protein 1, soluble CD40L, fatty acid binding protein, Lp-PLA 2 ).
Study population
157 asymptomatic individuals with mild to moderate risk of cardiovascular disease according to the HeartScore (6) and without a known acute or chronic infl ammatory disease nor liver or renal disease were enlisted to the study. The baseline physical characteristics are shown in Table 2 .
Randomization and follow-up
Eligible individuals willing to participate in the IVV study were (after the signing of informed consent) randomized into one of the two arms. Red or white wine was supplied in bottles directly to the participants' homes in the respective amount. Each participant also obtained a workbook with instructions to make notes about daily consumption of the study wine as well as other alcoholic beverages. Blood samples for the measurement of the laboratory endpoint and safety parameters were obtained at a randomization visit and then after one, six, and twelve months. All visits included a physical examination and assessment of cardiovascular events and other medical history since the last visit. At twelve months, after the fi nal visit, the wine supply was stopped. Participants were required to return the corks from the wine bottles to confi rm that they had drunk the wine rather than sold it. During the study period no specifi c restrictions and recommendations were made with respect to diet, lifestyle or possible diagnostic or therapeutic procedures.
Safety assessment
Liver enzymes (alanine aminotransferase, aspartate aminotransferase, gamma glutamyltransferase, alkaline phosphatase) were investigated during every visit. If any of the parameters exceeded threefold (>3x) the upper limit of normal range (ULN), an unscheduled safety visit was performed. If any of the liver enzymes remained >3x ULN for 14 days, wine consumption was to be stopped.
Statistical methods
Standard descriptive statistics were applied in the analysis: absolute and relative frequencies for categorical variables and mean supplemented by standard deviation for continuous variables. The statistical signifi cance of differences between groups of patients was computed using maximum likelihood chi-square test for categorical variables, independent t-test for continuous variables with two categories and analysis of variance (ANOVA) for three groups of patients; logarithmic transformation was applied when necessary. The change of parameters in time was tested by paired t-test.
The level of statistical signifi cance was set at a = 0.05. IBM SPSS 21 for Windows (Release 21.0.0, IBM Corporation 2012) was adopted in all analyses.
Results
Both groups were comparable in baseline physical characteristics (Tab. 2). The groups also did not differ in the baseline blood pressure values, liver function tests, fasting blood glucose level, and lipid parameters with the exception of total cholesterol, which was signifi cantly higher in the RW group (Tab. 3).
11 of 157 study participants (7 %) did not fi nish the 1-year follow up. 146 patients completed the study with complete records. Nobody had to stop wine consumption due to signifi cant liver enzyme elevation.
The level of HDL signifi cantly decreased at 6 months in the WW group in comparison with the baseline value (Tab. 4). How- ever, there was only a trend to lower HDL level in the WW group in the intergroup analysis at 6 months and no difference was observed in HDL levels at 12 months in both intra-and intergroup analyses (Tab. 4). The levels of TG were comparable between groups during the study.
On the other hand, we found signifi cant reduction in LDL in both groups at 6 and 12 months compared with the baseline. The LDL level was signifi cantly lower at 6 months in the WW group, however, it was not different at 12 months and the differences from baseline were comparable between the groups (Tab. 4).
Similarly, we observed a signifi cant reduction of TC in both groups at 6 months; at 12 months this effect reached statistical signifi cance only in the RW group, however, the differences from baseline were again comparable (Tab. 4).
The level of CRP was signifi cantly higher at 12 months in the WW group in comparison to the baseline value, however, no differences were found in the intergroup analysis (Tab. 5). Fasting blood glucose levels were signifi cantly reduced in both groups at 6 months; at 12 months we observed only a trend towards lower glucose levels in comparison with baseline values in the RW group; no differences were found in glucose levels in the intergroup comparison at 6 or 12 months (Tab. 5).
The Lp-PLA 2 levels at 12 months were signifi cantly lower in the RW group both in comparison with the WW group and in comparison with baseline values (Tab. 6, Fig. 1 ). However, in the WW group we also found a trend to reduced Lp-PLA 2 values in comparison to baseline levels and both groups had comparable differences from baseline (Tab. 6, Fig. 1 ). We also demonstrated a trend towards copeptin level reduction in the RW group at 12 months in comparison with the baseline value but no differences were detected in the intergroup analysis (Tab. 6, Fig. 1 ).
We did not detect any differences in the levels of ALT, GGT or bilirubin (Tab. 7). Only a trend towards lower AST level was found in the WW group at 12 months in comparison with baseline values, with no difference in the intergroup analysis (Tab. 7). The levels of ALP were signifi cantly reduced in both groups at 6 and at 12 months, this effect was comparable in the intergroup analyses (Tab. 7) .
No clinically relevant differences were found in any other parameters. No clinically relevant differences were found in any of the measured parameters after adjusting for gender and age.
Discussion
There is a large body of evidence that the Mediterranean diet and light to moderate alcohol consumption, in particular red wine, are associated with less cardiovascular diseases and an improved lipid profi le (7) . However, it is still not clear whether alcohol per se or other components of alcoholic beverages protect against heart disease (8) . A number of studies demonstrated that alcohol per se exhibits a protective effect (3, 9) . On the other hand, several authors described cardio-protective properties of other components, particularly fl avonoids (10) .
Currently there are confl icting results regarding the comparison of the effects of red and white wines on different clinically relevant endpoints in experimental as well as in small clinical studies (11-13). It is well known that there are major differences in basic characteristics between red and white wines. Red wine exhibits a higher antioxidant capacity and, according to several studies, a protective effect against LDL-oxidation when compared with white wine (14) . Rosenkranz et al (15) and Sparwel et al (16) have shown attenuation of platelet-derived growth factor receptor (PDGFR) signalling (an important pathogenic mechanism in the development of atherosclerosis) in rat and human vascular smooth muscle cells (VSMCs) induced by red wine, whereas white wine had no effect. On the other hand, Munday et al (11) did not fi nd any differences between red and white wine in serum lipoprotein profi le and fatty streak formation in the C57BL/6 mouse atherosclerosis model. López et al (17) observed a similar reduction in superoxide production and an increase in expression and activity of NO-synthase (iNOS) by dealcoholized red and white wines in a rat model, while up-regulation of cyclo-oxygenase-2 (COX-2) was detected only in the red wine group. Moreover, Auger et al (18) described that both red wine and polyphenols-enriched white wine prevent early atherosclerosis in hamsters. Regarding the effects on atherosclerosis, there is only limited evidence from prospective head-to-head comparisons of different alcoholic beverages in human subjects; the published studies were focused mostly on the acute effects of drinking. Tousoulis et al (19) observed reactive hyperaemia after beer and red wine consumption that was not detected after white wine, whiskey or water in healthy young individuals. A reduction in urinary prostaglandin PGF2α-III as a marker of oxidative stress was expressed more after red wine than after white wine in a study on healthy subjects by Pignatelli et al (20) . Pace-Asciak et al (21) did not fi nd any advantage in red wine over white wine in preventing platelet aggregation in healthy males. A similar increase in total antioxidant capacity as a result of red or white wine consumption was described by Pinzani et al (22) .
Williams et al. (12) did not observe any signifi cant difference in the acute effects of red and white wine drinking on blood pressure, heart rate, plasma lipids, levels of interleukin-6 (IL-6), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in males with angiographic evidence of coronary artery disease (CAD). Moreover, a comparable acute improvement of endothelial function after red and white wine drinking was reported by Whelan et al (13) in subjects with proven CAD. Blann et al (23) described an increase in beta-thromboglobulin levels after red wine, whereas white wine had no effect.
Until now, the longest exposure to red and white wines in a prospective trial was examined by Sacanella et al (24) in their four-week study; in a group of thirty-six healthy females they found a stronger anti-infl ammatory effect of red wine compared with white wine consumption.
To the best of our knowledge, the IVV trial is the fi rst longterm, randomized, prospective study focused on the comparison of the effects of regular white and red wine drinking on several markers of atherosclerosis. Despite there being signifi cant differences in the composition of the red and white wine used in this study (e.g. resveratrol concentration or antioxidant capacity) (Tab. 1), we are unable to demonstrate any clinically important differences in the effects of both wines on monitored parameters. We cannot, therefore, confi rm our primary hypothesis that red wine consumption is associated with higher levels of HDL in comparison with white wine. In the IVV trial we compared the effects of consumption of red wine with a high concentration of fl avonoids and other antioxidants and white wine with a low concentration of these components and we were unable to fi nd any clinically important differences in biomarkers of atherosclerosis.
It has been repeatedly shown that wine drinking is associated with several changes in lipid profi le. The data in the literature are almost consistent in showing that wine consumption decreases the levels of LDL while it increases the levels of HDL (8, 25, 26) .
In concordance with these literature data, we observed a highly signifi cant and lasting effect of wine consumption on LDL reduction that was observed in both 6-month and 12-month blood samples. Contrary to the previously published studies, however, we found a transient and weak reduction of HDL after 6 months of white wine consumption. This effect was no more detectable after 12 months. Neither white wine nor red wine drinking was associated with an increase of HDL levels. We can speculate that the inability to demonstrate any elevation of HDL levels in our study could be at least partially caused by the different design of the IVV trial in comparison with the previously published studies: whereas the IVV trial was a prospective and long-term intervention, the literature evidence for an increase of HDL after wine consumption comes mostly from retrospective or small and short-term prospective studies. Moreover, abstinence from alcohol was not required for subject enrolment in our study and therefore the baseline HDL levels could be already elevated as a result of previous drinking; however, in that case we would not expect further reduction of LDL.
We also found a signifi cant elevation in CRP levels at the 12-month follow-up in the WW group and in the total study population. There are confl icting literature data on the effects of wine consumption on infl ammatory markers. Our results are in contra- diction with the results from retrospective studies (27). On the other hand, an increase in plasma pro-infl ammatory cytokines consistent with our results has been described in a small prospective trial (12) . Current evidence on the effects of alcohol consumption on blood glucose levels has also produced inconsistent data. Our observation of transient signifi cant fasting blood glucose reduction is consistent with several previously published studies (28) .
Unaffected liver function tests (levels of gama-glutamyltransferase, aspartate-aminotransferase, and alanine-aminotransferase) in our study may demonstrate the liver safety of long-term moderate wine consumption. A reduction of alkaline phosphatase activity as a result of alcohol drinking observed in our study was already previously described by several authors (29) . Our results showing decreased Lp-PLA 2 levels after 12 months of wine consumption confi rm prospectively the results of previous retrospective studies (30) . We also did not fi nd any differences in copeptin levels and we, therefore, demonstrated for the fi rst time that copeptin levels are not infl uenced by wine drinking.
Our study has several limitations. Possible biases may be caused by the limited size of the study population. The eligible subjects for study participation were also not required to abstain from alcohol consumption before enrolment. Furthermore, although all participants were strongly encouraged to restrict their alcohol consumption to the study wine and to comply with the recommended doses, the occasional drinking of more alcohol or other alcoholic beverages was not strictly forbidden and was not being assessed as a protocol violation. The reason for this approach was to refl ect real life conditions as much as possible in the IVV trial.
Conclusion
In this prospective, randomized trial we did not fi nd any clinically relevant differences in the lipid profi le, CRP, fasting blood glucose, other markers of atherosclerosis i.e. Lp-PLA 2 or copeptin, and liver function tests, between long-term consumption of red and white wine. Moreover, we were unable to confi rm the hypothesis, mostly from retrospective studies, that wine drinking is associated with an elevation of HDL.
